SCHEMBL2940455

SCHEMBL2940455

COc1ccc(CNc2ccc3ncc(-c4ccc(Cl)cc4)n3n2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 14/20 0.78
MKNK1 Q9BUB5 3/20 0.66
PIM1 P11309 2/20 0.64
JAK2 O60674 1/20 0.55
ABL1 P00519 1/20 0.55
NTRK1 P04629 1/20 0.55
INSR P06213 1/20 0.55
LCK P06239 1/20 0.55
CSF1R P07333 1/20 0.55
LYN P07948 1/20 0.55
RET P07949 1/20 0.55
IGF1R P08069 1/20 0.55
MET P08581 1/20 0.55
ROS1 P08922 1/20 0.55
PDGFRB P09619 1/20 0.55
FGR P09769 1/20 0.55
KIT P10721 1/20 0.55
SRC P12931 1/20 0.55
BRAF P15056 1/20 0.55
FLT1 P17948 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951694 0.94 FYN (0.78) FYNMKNK1PIM1JAK2ABL1
SCHEMBL2940129 0.90 FYN (0.73) FYNMKNK1PIM1JAK2ABL1
SCHEMBL1054209 0.90 FYN (0.76) FYNMKNK1PIM1JAK2ABL1
SCHEMBL1055522 0.89 FYN (0.74) FYNMKNK1PIM1JAK2ABL1
SCHEMBL2948785 0.89 FYN (0.76) FYNMKNK1PIM1JAK2ABL1
SCHEMBL2943534 0.89 FYN (0.76) FYNMKNK1PIM1JAK2ABL1
SCHEMBL16623011 0.89 FYN (0.77) FYNMKNK1PIM1JAK2ABL1
SCHEMBL2942619 0.89 FYN (0.77) FYNPIM1
SCHEMBL18613351 0.88 FYN (1.00) FYNMKNK1PIM1NTRK1NTRK3
SCHEMBL2943172 0.86 FYN (0.69) FYNMKNK1PIM1JAK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
WO-2007025540-A2 SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 FYN 421/4885MKNK1 144/4885PIM1 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.